AbbVie 2026 Pipeline and Regulatory Outlook: Key Highlights and Expectations

Key highlights: AbbVie pipeline development and anticipated regulatory submissions in 2026 (from Q1 2026 earnings call excerpts)

1) Immunology/dermatology: new U.S. regulatory submission plus expanding combo strategy

• Rinvoq in Alopecia Areata (dermatology): AbbVie highlighted U.S. regulatory submissions of Rinvoq for alopecia areata, positioning it as a potential new source of growth in dermatology. ¹
• Crohn’s platform (Skyrizi + AbbVie’s 382 + later TL1A): AbbVie reported promising interim results from a Crohn’s platform study combining Skyrizi and alpha 4 beta 7 (382) and described the program’s intent to deepen efficacy (including doubling endoscopic data in the remarks). ¹²
  • Operationally, management described a Phase IIb plan to optimize the 382 exposure with higher-dose 382 in combination with Skyrizi, including monthly dosing/co-formulation work and discussions with regulators about possible acceleration. ²
  • They also indicated TL1A is expected to be added into the platform and that they will study it in ulcerative colitis along with Crohn’s. ²

What this implies for 2026 submissions (stated directionally, not a specific NDA date):

• The company’s CROHN’s platform is set up to support future regulatory actions, but the excerpts do not name a specific 2026 U.S. submission for this combo. Instead, they emphasize possible acceleration and a timeline where Phase III could start in roughly ~2 years depending on data and regulatory interaction. ²

---

2) Immunology: additional regulatory-related timing in psoriasis/other programs is present but not described as “upcoming in 2026”

• The excerpts include detailed immunology commercial discussion around Skyrizi and a CRL for an aesthetics application driven by manufacturing questions, with management stating there were no issues related to safety, efficacy, or labeling and that the FDA had not requested additional clinical trials. ³
  • This CRL pertains to an aesthetics application and therefore reflects a regulatory milestone, but the excerpt does not provide a clear “2026 resubmission date.” ³

---

3) Obesity/metabolism: ABBV-295 regulatory pathway into later stages (with 2026 study expectations)

• AbbVie announced early-stage data for ABBV-295 (long-acting amylin analog) showing clinically meaningful weight loss of nearly 10% after 12 weeks with mostly mild and transient GI adverse events and no cases of severe nausea, vomiting, or diarrhea. ⁴
• For development progression toward regulatory submission:
  • AbbVie expects Phase I interim data in obese patients later in 2026, a Phase II program beginning in Q3 2026, and described additional dosing regimens being tested (every-other-week and monthly). ⁴

Regulatory submission implication:

• The excerpt frames 2026 mainly as continued clinical development (Phase II initiation and interim Phase I data), not as a near-term NDA/BLA submission in 2026. ⁴

---

4) Oncology: multiple programs with 2026-centric regulatory submission expectations and acceleration signals

A) Solid tumor/other oncology: tempo for regulatory submissions (“expected by end of this year,” which likely maps into 2026 execution)

• Management said it is now expecting the regulatory submission for an indiscernible oncology asset by the end of this year, and that this timing is earlier than previous expectations. ¹
  • The excerpt does not name the drug/indication in the text provided (it appears bracketed/indiscernible), so the exact regulatory filing target cannot be identified from the excerpt alone. ¹

B) Crohn’s oncology asset is distinct; hematologic oncology provides explicit potential timing for regulatory submissions “later this year”

• In hematologic oncology, AbbVie described a Phase III trial for monotherapy in third-line plus multiple myeloma, tracking ahead of schedule, with a response rate readout in Q3 and an interim progression-free survival analysis. ³
• They stated that if the interim analysis is positive, regulatory submissions would occur later this year. ³
  • Again, the excerpt doesn’t specify whether these submissions are U.S.-only, global, or the exact filing type, but it is a clear conditional regulatory timing statement. ³

C) Solid tumor (Temab-A): strategy change supports later-phase execution and planned data readouts

• AbbVie updated its colorectal cancer strategy to focus on Temab-A + bevacizumab in an all-comers Phase III instead of Temab-A monotherapy in cMET-selected patients. ⁵
• The excerpt provides quantitative efficacy context (e.g., objective response rate of 30% and confirmed disease control rate of 97% for the combination) and states initial data readout is expected in the second half of next year. ⁵
  • This is relevant to “upcoming submissions” because Phase III data timing typically drives filings, but the excerpt does not explicitly state a 2026 regulatory submission date for Temab-A. ⁵

D) ASCO/acceleration discussion in prostate and other programs

• AbbVie said AbbV-706 and other oncology trials are progressing, including a Phase III trial begun in relapsed/refractory small cell lung cancer and planning Phase II studies to initiate in 2026. ⁵
• They also stated that 96 dose escalation data in late-line metastatic castration-resistant prostate cancer will be presented at ASCO, and that based on those results they are discussing acceleration options with regulators to advance into Phase III trials as quickly as possible. ⁵

Bottom line for oncology 2026 submissions (from the excerpts):

• There is at least one program with explicit language: a regulatory submission expected by the end of “this year” (earlier than prior expectations). ¹
• There is also a conditional regulatory pathway in hematologic oncology where positive interim results could trigger regulatory submissions later this year. ³
• Other oncology updates (Temab-A, 706, prostate acceleration discussions) are aimed at future regulatory actions but don’t specify a precise “submission in 2026” in the provided text. ⁵

---

Summary table (only what the excerpts directly support)

---

Overall “upcoming in 2026” regulatory theme (grounded in the excerpts)

• AbbVie’s regulatory momentum into 2026 is strongest where the company explicitly states regulatory submissions (Rinvoq Alopecia Areata in the U.S.) and where it explicitly provides filing timing language for oncology assets (“by the end of this year,” or “later this year” if interim is positive). ¹³
• For other areas (e.g., obesity ABBV-295 and Crohn’s platform), the excerpt emphasizes clinical progression and interim/Phase transition milestones in 2026, which typically precede later regulatory filings, but the excerpt does not give a direct “submission in 2026” date for those programs. ²⁴